Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAsan Medical Center
About this trial
This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.
Eligibility criteria
Qualifiers
Patients who underwent stereotactic radiosurgery (SRS, gamma-knife radiosurgery or cyberknife radiosurgery) for brain metastases
One to ten newly diagnosed brain metastases
Patients without acute neurological symptom
Patients with a Karnofsky performance status score of 70 or higher
Disqualifiers
Patients who have undergone prior brain surgery, SRS, or whole-brain radiation therapy.
Patients who are diagnosed with leukemia, lymphoma, germ-cell tumor, small-cell lung cancer, leptomeningeal disease, or unknown primary tumor.
Patients with age < 18 years.
Patients without baseline MRI.
Trial design
Treatments tested in this trial
- Magnetic resonance imaging (MRI)
- Diffusion-weighted MRI
- Arterial spin labeling (ASL)
- Dynamic susceptibility contrast-MRI (DSC-MRI)
Treatment groups
132 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov